Welcome to our dedicated page for Senestech SEC filings (Ticker: SNES), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SenesTech, Inc. (NASDAQ: SNES) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. SenesTech is a biotechnology company focused on fertility control for managing rodent populations, and its filings offer detailed information on its operations, financing activities, and governance.
Key documents available through EDGAR and summarized with AI-powered insights include Form 10-K annual reports, which describe the business, risk factors, and strategy around products such as ContraPest® and the Evolve rodent birth control line, and Form 10-Q quarterly reports, which update investors on revenues, gross margins, operating expenses, and cash position. These periodic reports help readers understand how SenesTech’s fertility control products and multi-channel distribution efforts are reflected in its financial statements.
SenesTech also files numerous Form 8-K current reports documenting material events. Recent 8-K filings describe warrant inducement agreements and related financings, at-the-market offering prospectus supplements, the appointment and compensation of an interim chief operating officer, board changes, and the release of quarterly financial results. These filings provide structured detail on capital raises, equity-linked securities, and key management decisions.
Through this page, users can also review registration statements and prospectus supplements referenced in 8-Ks, which outline at-the-market equity programs and additional registered shares. Stock Titan’s tools surface new filings in real time and apply AI-generated summaries to highlight the main points of lengthy documents, helping investors quickly locate information on SenesTech’s financial condition, equity offerings, and significant corporate events without reading every page manually.
Glenbrook Capital Management-related entities acquired additional SenesTech, Inc. shares in the open market. On the reported date, PFS Trust, the Glenbrook Capital Management Inc. Employee Profit-Sharing Plan, and various managed funds together purchased 3,000 shares of SenesTech common stock at $1.469 per share, bringing their indirect holdings reported in this filing to 893,635 shares. Glenbrook Capital Management, as investment manager, disclaims beneficial ownership beyond any pecuniary interest.
SenesTech, Inc. is asking stockholders to vote at its June 9, 2026 annual meeting on board elections, executive pay and key governance items. Two Class I directors, Jake S. Leach and Joshua M. Moss, are nominated for new three-year terms. Stockholders will cast a non-binding say-on-pay vote on 2025 compensation for the CEO and other named executives, and vote on amending the 2018 Equity Incentive Plan to add 1,700,000 shares of common stock for future equity awards. They will also vote on ratifying M&K CPAS, PLLC as independent auditor for 2026. Holders of 5,265,744 shares outstanding as of April 20, 2026 may vote by internet, telephone, mail or in person, with detailed rules for quorums, broker non-votes and proposal approval thresholds.
SenesTech, Inc. disclosure: Glenbrook Capital Management reports beneficial ownership of 890,635 shares of Common Stock, representing 16.8% of the class based on 5,303,426 shares outstanding as of March 11, 2026. The filing states these shares are held by affiliated vehicles, including PFS Trust, and that shared voting and dispositive power is reported.
SenesTech, Inc. reported that entities managed by Glenbrook Capital Management made open-market purchases of a total of 171,034 shares of Common Stock on March 13, 16 and 17, 2026, at prices between $1.79 and $1.95 per share.
After these transactions, the Glenbrook-managed accounts indirectly held 890,635 SenesTech shares. A footnote explains that this filing also corrects a prior understatement of beneficially owned shares in an earlier Form 4.
SenesTech, Inc. files its annual report describing a rodent fertility-control business built around ContraPest liquid bait and Evolve Rat and Evolve Mouse soft baits. These products target reproduction rather than killing, are positioned within integrated pest management programs, and benefit from minimum-risk or EPA registrations.
The company highlights growing regulatory scrutiny of anticoagulant rodenticides and positions its non-lethal, environmentally focused products as alternatives. It reports net losses of $6.4 million in 2025 and $6.2 million in 2024, with an accumulated deficit of $142.5 million, and warns it will need additional capital and broader market adoption to reach profitability.
SenesTech, Inc. reported 2025 results showing faster growth but continuing losses. Full-year revenue rose 20% to $2.2 million, driven mainly by e-commerce, while gross margin improved to 62.5% from 54.1% as higher-margin Evolve products and manufacturing efficiencies took hold.
The company posted a 2025 net loss of $6.4 million versus $6.2 million in 2024. Adjusted EBITDA loss improved to $5.3 million from $5.8 million, and Adjusted Net Loss was $5.6 million after excluding one-time legal and non-cash lease expenses. E-commerce revenue grew 88% year over year and now accounts for more than half of total revenue.
Capital raises in 2025 lifted cash and short-term investments to $8.6 million at year-end, and the company believes this provides operating runway through approximately the second quarter of 2027. SenesTech highlighted strong field data for its Evolve rodent birth control, international expansion into New Zealand and Belize, and a CEO transition with an Interim Executive Chair appointed while a formal search for a new CEO is underway.
SenesTech, Inc. reported that Glenbrook Capital Management, acting as investment manager for PFS Trust and the Glenbrook Capital Management Inc. Employee Profit-Sharing Plan, indirectly bought a total of 85,901 shares of Common Stock on February 17–19, 2026.
The shares were purchased in open-market transactions at prices between $2.29 and $2.402 per share, increasing these entities’ reported indirect holdings to 704,211 shares of SenesTech Common Stock.
Glenbrook Capital Management, a 10% owner of SenesTech, Inc. (SNES), reported three indirect open-market purchases of common stock. On February 11, 12, and 13, 2026, investment entities it manages bought 8,000, 7,956, and 15,390 SenesTech common shares at per-share prices between $1.7205 and $1.8912. After these transactions, a total of 633,700 common shares were reported as beneficially owned on an indirect basis. The shares are held by PFS Trust and the Glenbrook Capital Management Inc. Employee Profit-Sharing Plan, with Glenbrook acting as investment manager and disclaiming beneficial ownership except to the extent of any pecuniary interest.
Glenbrook Capital Management, identified as a 10% owner of SenesTech, Inc., reported indirect purchases of the company’s common stock through entities it manages. On February 4, 2026, PFS Trust and Glenbrook Capital Management Inc. Employee Profit-Sharing Plan together bought 5,685 shares at $1.8247 per share. On February 5, 2026, they acquired another 2,884 shares at $1.7705 per share. After these transactions, the managed accounts held a total of 602,354 SenesTech common shares indirectly. Glenbrook Capital Management serves as investment manager to these entities and disclaims beneficial ownership of the securities except to the extent of any pecuniary interest.
Glenbrook Capital Management, as reporting person, disclosed two indirect open‑market purchases of SenesTech, Inc. common stock made for PFS Trust and an employee profit‑sharing plan. On January 30, 2026, 5,399 shares were bought at $1.8718 per share. On February 2, 2026, 42,739 shares were bought at $1.9752 per share.
After these trades, 551,046 and then 593,785 SenesTech shares were reported as indirectly beneficially owned. The filing notes that Glenbrook Capital Management serves as investment manager to the entities holding the shares and disclaims beneficial ownership except to the extent of any pecuniary interest.